Niagen Bioscience, Inc. (formerly ChromaDex Corp.) Overview
Pro stress-test →ChromaDex/Niagen is a global bioscience company dedicated to healthy aging, pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Tru Niagen® is positioned as the number one healthy-aging NAD+ supplement in the United States.
Strategic Profile
Pro stress-test →The company operates through three segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services, with the majority of revenue from Consumer Products. The company has partnered with multiple research institutions including the National Institutes of Health and Northwestern University Feinberg School of Medicine to study nicotinamide riboside benefits.
Competitive Landscape
Pro stress-test →Niagen competes in the growing healthy aging and NAD+ supplement market against established supplement brands and emerging longevity companies. Key rivals include Elysium Health (Basis NAD+ booster), other NAD+ precursor manufacturers, and broader premium supplement makers targeting aging consumers. The market is emerging but not yet commoditized, and Niagen's patent-protected formulation and clinical research partnerships provide defensibility.
Industry Context
Niagen Bioscience, Inc. (formerly ChromaDex Corp.) operates in NAD+ and healthy aging supplements.
Key facts
Founded: 1999 · Headquarters: Los Angeles, US · Employees: Unknown · Revenue: $31.5M (Q1 2026) · Market cap: $230.79M